TIF News (IT)

On February 12, in an appraisal consultation document, the UK National Institute for Health and Care Excellence (NICE) recommended against the use of Bluebird Bio’s Zynteglo (betibeglogene autotemcel) gene therapy for the…

TIF joins forces with 300 million people around the world for the global observance of Rare Disease Day, coming up on February 28th. Rare Disease Day is an annual awareness…

The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird bio that the latter has placed Phase 1/2 and Phase…

Gene therapy for thalassaemia is an expensive and complex procedure, with great efforts ongoing currently by all involved stakeholders, such as patients, healthcare professionals, etc. to ensure its accessibility and…

Access to quality-assured medical products improves health and saves lives. Nevertheless, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 10%…

We are very proud to inform you that TIF remains in official relations with the World Health Organization (WHO) for 2021-2024 The extension of ΤIF’s official relations with WHO was…

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing…

by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for quality standards and blood, tissues and cells. This framework is…